# A Phase I Clinical Study to Evaluate the PK, PD, Efficacy, and Safety of GB18 Injection in Patients With Tumor Cachexia

> **NCT07519564** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Kexing Biopharm Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Cachexia; Cancer

## Interventions

- **DRUG:** GB18

## Key facts

- **NCT ID:** NCT07519564
- **Lead sponsor:** Kexing Biopharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07519564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07519564, "A Phase I Clinical Study to Evaluate the PK, PD, Efficacy, and Safety of GB18 Injection in Patients With Tumor Cachexia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07519564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*